Found: 51
Select item for more details and to access through your institution.
Prospective assessment using <sup>18</sup>F-FDG PET/CT as a novel predictor for early response to PD-1 blockade in non-small-cell lung cancer.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-15964-3
- By:
- Publication type:
- Article
Synchronous dilemma of sarcoid-like reaction and drastic response after PD-1 blockade administration in lung cancer.
- Published in:
- Japanese Journal of Clinical Oncology, 2021, v. 51, n. 7, p. 1179, doi. 10.1093/jjco/hyab043
- By:
- Publication type:
- Article
Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer.
- Published in:
- Cancer Imaging, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s40644-023-00538-x
- By:
- Publication type:
- Article
Clinical Issue of Myasthenia Gravis Related to Immune Checkpoint Inhibitors.
- Published in:
- Current Oncology Reports, 2024, v. 26, n. 9, p. 1113, doi. 10.1007/s11912-024-01571-0
- By:
- Publication type:
- Article
Progression to Lymph Node Metastasis After Spontaneous Regression of Pulmonary Adenocarcinoma Following Biopsy.
- Published in:
- In Vivo, 2024, v. 38, n. 3, p. 1498, doi. 10.21873/invivo.13597
- By:
- Publication type:
- Article
Severe Thrombocytopenia Associated With Pembrolizumab in Patients With Non-small Cell Lung Cancer (NSCLC): A Case Report and Literature Review.
- Published in:
- In Vivo, 2020, v. 34, n. 2, p. 877, doi. 10.21873/invivo.11852
- By:
- Publication type:
- Article
Metachronous lesions in the orbit, retroperitoneum, and pleura of mucosa‐associated lymphoid tissue lymphoma: A case report.
- Published in:
- Cancer Reports, 2022, v. 5, n. 10, p. 1, doi. 10.1002/cnr2.1689
- By:
- Publication type:
- Article
Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer.
- Published in:
- Journal of Clinical Medicine, 2020, v. 9, n. 3, p. 725, doi. 10.3390/jcm9030725
- By:
- Publication type:
- Article
A Pilot Study of Transdermal Application of Diphenhydramine to the Nasal Ala in Patients with Allergic Rhinitis and Asthma.
- Published in:
- Tokai Journal of Experimental & Clinical Medicine, 2022, v. 47, n. 4, p. 170
- By:
- Publication type:
- Article
A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress).
- Published in:
- 2020
- By:
- Publication type:
- journal article
Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 1066, doi. 10.1007/s10637-022-01269-9
- By:
- Publication type:
- Article
Clinical significance of antinuclear antibody as prognostic marker for first-line pembrolizumab in advanced non-small cell lung cancer.
- Published in:
- International Journal of Clinical Oncology, 2024, v. 29, n. 2, p. 124, doi. 10.1007/s10147-023-02445-4
- By:
- Publication type:
- Article
Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B).
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B).
- Published in:
- International Journal of Clinical Oncology, 2022, v. 27, n. 1, p. 112, doi. 10.1007/s10147-021-02043-2
- By:
- Publication type:
- Article
Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade Drugs.
- Published in:
- Journal of Clinical Medicine, 2021, v. 10, n. 16, p. 3744, doi. 10.3390/jcm10163744
- By:
- Publication type:
- Article
Clinical Outcome of Nivolumab Plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by Durvalumab.
- Published in:
- Cancers, 2024, v. 16, n. 7, p. 1409, doi. 10.3390/cancers16071409
- By:
- Publication type:
- Article
Salvage Chemotherapy in Patients with Previously Treated Thymic Carcinoma.
- Published in:
- Cancers, 2021, v. 13, n. 21, p. 5441, doi. 10.3390/cancers13215441
- By:
- Publication type:
- Article
Real‐world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive‐disease small‐cell lung cancer.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 1, p. 73, doi. 10.1002/cam4.4938
- By:
- Publication type:
- Article
Pretreatment Glasgow prognostic score predicts survival among patients with high PD‐L1 expression administered first‐line pembrolizumab monotherapy for non‐small cell lung cancer.
- Published in:
- Cancer Medicine, 2021, v. 10, n. 20, p. 6971, doi. 10.1002/cam4.4220
- By:
- Publication type:
- Article
Tumor immunity is related to <sup>18</sup>F‐FDG uptake in thymic epithelial tumor.
- Published in:
- Cancer Medicine, 2021, v. 10, n. 18, p. 6317, doi. 10.1002/cam4.4176
- By:
- Publication type:
- Article
Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. N.PAG, doi. 10.3389/fonc.2021.610952
- By:
- Publication type:
- Article
A case of cerebral infarction due to pleomorphic carcinoma of the lung.
- Published in:
- Surgical Neurology International, 2020, v. 11, p. 1, doi. 10.25259/SNI_37_2020
- By:
- Publication type:
- Article
Multiple tuberculous nodules with metachronous changes: a case report.
- Published in:
- 2013
- By:
- Publication type:
- Case Study
Efficacy and Safety of Anti-Programed Death-1 Blockade in Previously Treated Large-Cell Neuroendocrine Carcinoma.
- Published in:
- Chemotherapy (0009-3157), 2021, v. 66, n. 3, p. 65, doi. 10.1159/000514841
- By:
- Publication type:
- Article
Clinicopathological impact of VEGFR2 and VEGF‐C in patients with EGFR‐major mutant NSCLC receiving osimertinib.
- Published in:
- Thoracic Cancer, 2023, v. 14, n. 29, p. 2950, doi. 10.1111/1759-7714.15082
- By:
- Publication type:
- Article
Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non‐small cell lung cancer.
- Published in:
- Thoracic Cancer, 2022, v. 13, n. 10, p. 1479, doi. 10.1111/1759-7714.14417
- By:
- Publication type:
- Article
Clinical impact of post‐progression survival on overall survival in patients receiving nivolumab monotherapy as a second‐line treatment for advanced non‐small cell lung cancer.
- Published in:
- Thoracic Cancer, 2021, v. 12, n. 8, p. 1171, doi. 10.1111/1759-7714.13886
- By:
- Publication type:
- Article
Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure.
- Published in:
- Thoracic Cancer, 2021, v. 12, n. 6, p. 864, doi. 10.1111/1759-7714.13864
- By:
- Publication type:
- Article
Pre‐existing interstitial lung disease does not affect prognosis in non‐small cell lung cancer patients with PD‐L1 expression ≥50% on first‐line pembrolizumab.
- Published in:
- Thoracic Cancer, 2021, v. 12, n. 3, p. 304, doi. 10.1111/1759-7714.13725
- By:
- Publication type:
- Article
Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events.
- Published in:
- Thoracic Cancer, 2020, v. 11, n. 5, p. 1280, doi. 10.1111/1759-7714.13394
- By:
- Publication type:
- Article
Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non‐small cell lung cancer harboring EGFR mutation.
- Published in:
- Thoracic Cancer, 2020, v. 11, n. 4, p. 1045, doi. 10.1111/1759-7714.13363
- By:
- Publication type:
- Article
Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer.
- Published in:
- Thoracic Cancer, 2019, v. 10, n. 4, p. 975, doi. 10.1111/1759-7714.13039
- By:
- Publication type:
- Article
Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab.
- Published in:
- Thoracic Cancer, 2019, v. 10, n. 4, p. 992, doi. 10.1111/1759-7714.13044
- By:
- Publication type:
- Article
Clinical significance of primary prophylactic pegylated‐granulocyte‐colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non‐small cell lung cancer.
- Published in:
- Thoracic Cancer, 2019, v. 10, n. 4, p. 1005, doi. 10.1111/1759-7714.13022
- By:
- Publication type:
- Article
Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients.
- Published in:
- Thoracic Cancer, 2019, v. 10, n. 4, p. 775, doi. 10.1111/1759-7714.12998
- By:
- Publication type:
- Article
Survey of malignant pleural mesothelioma treatment in Japan: Patterns of practice and clinical outcomes in tomotherapy facilities.
- Published in:
- Journal of Radiation Research, 2022, v. 63, n. 2, p. 281, doi. 10.1093/jrr/rrab127
- By:
- Publication type:
- Article
Correction to: Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.
- Published in:
- 2020
- By:
- Publication type:
- corrected article
Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Respiratory failure associated with hypoventilation in a patient with severe hypothyroidism.
- Published in:
- Respirology Case Reports, 2014, v. 2, n. 2, p. 79, doi. 10.1002/rcr2.55
- By:
- Publication type:
- Article
Tumor metabolic volume by <sup>18</sup>F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%.
- Published in:
- Scientific Reports, 2020, v. 10, n. 1, p. N.PAG, doi. 10.1038/s41598-020-71735-y
- By:
- Publication type:
- Article
Cough challenge tests involving mechanical stimulation of the cervical trachea in patients with cough as a leading symptom M Kamimura et al. Tracheal cough challenge tests.
- Published in:
- Respirology, 2010, v. 15, n. 8, p. 1244, doi. 10.1111/j.1440-1843.2010.01859.x
- By:
- Publication type:
- Article
Clinical Utility of Inflammatory and Nutritious Index as Therapeutic Prediction of Nivolumab plus Ipilimumab in Advanced Non-Small Cell Lung Cancer.
- Published in:
- Oncology, 2024, v. 102, n. 3, p. 271, doi. 10.1159/000534169
- By:
- Publication type:
- Article
Post-Progression Survival Influences Overall Survival among Patients with Advanced Non-Small Cell Lung Cancer Undergoing First-Line Pembrolizumab Monotherapy.
- Published in:
- Oncology, 2021, v. 99, n. 9, p. 562, doi. 10.1159/000516745
- By:
- Publication type:
- Article
Clinical Outcomes of Second‐Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study.
- Published in:
- Oncologist, 2020, v. 25, n. 4, p. e668, doi. 10.1634/theoncologist.2019-0593
- By:
- Publication type:
- Article
Clinical impact of inflammatory and nutrition index based on metabolic tumor activity in non‑small cell lung cancer treated with immunotherapy.
- Published in:
- Oncology Letters, 2024, v. 27, n. 3, p. N.PAG, doi. 10.3892/ol.2024.14243
- By:
- Publication type:
- Article
Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer.
- Published in:
- Oncology Letters, 2023, v. 25, n. 3, p. N.PAG, doi. 10.3892/ol.2023.13696
- By:
- Publication type:
- Article
Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2022.1080729
- By:
- Publication type:
- Article
Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status.
- Published in:
- Medicina (1010660X), 2021, v. 57, n. 11, p. 1, doi. 10.3390/medicina57111273
- By:
- Publication type:
- Article
Potential of VEGFR2 expression as a predictive marker of PD-1 blockade in patients with advanced NSCLC.
- Published in:
- Oncology Reports, 2022, v. 48, n. 6, p. N.PAG, doi. 10.3892/or.2022.8429
- By:
- Publication type:
- Article